Date de l'évènement:
Lundi, 14 Septembre, 2020
The article targets the general public ans describes how Vect-Horus is developing drug-conjugated vectors that bind to BBB receptors with high-affinity, triggering transport into and across cells to deliver drugs or imaging agents to the brain and cancer tissues.
To learn more, visit the Nature Biotech site or read the article in September 2020 digital edition of the magazine (page 42-43)
